Results 281 to 290 of about 16,336,802 (316)

Disclosure, Verification, and Value: The Impact of Climate Risk Disclosure on Institutional On‐Site Research and Economic Consequences

Business Strategy and the Environment, EarlyView.
ABSTRACT Based on signaling theory and information asymmetry theory, this study uses a sample of Chinese A share listed firms from 2012 to 2023 to examine the effect of climate risk disclosure (CRD) on institutional on‐site research and its economic consequences.
Sha Tang, Chante Jian Ding, Abdullahi D. Ahmed   +2 more
wiley   +1 more source

Effect of Dhatuvriddhikara Churna (Ayurveda Herbal Formulation) and Haritakyadi Yoga Koshthashodhana (Therapeutic Purgation) in the Kshinashukra (Oligoasthenospermia) - A Structured Study Protocol of Open Labelled Randomized Placebo-Controlled Trial

Nurooddin Hajruddin Khan, Mandip Goyal
openalex   +2 more sources

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

Clinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N. Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert   +8 more
wiley   +1 more source

Triglyceride Polygenic Score Identifies Individuals Who May Respond Differently to Aspirin in Primary Prevention

Clinical Pharmacology &Therapeutics, EarlyView.
Low‐dose aspirin is no longer routinely recommended for the primary prevention of cardiovascular disease in older adults due to a lack of net benefit over bleeding risk. We hypothesized that genetic subgroups may experience differential harm or benefit from aspirin therapy.
Peter D. Fransquet, Chenglong Yu, Cammie Tran, Sultana Monira Hussain, Chad A. Bousman, Mark R. Nelson, Andrew M. Tonkin, John J. McNeil, Paul Lacaze   +8 more
wiley   +1 more source

Model‐Informed Approaches for Pediatric Type 2 Diabetes Evidence Generation: Insights from a Model‐Based Longitudinal HbA1c Meta‐Analysis from EMA Marketing Authorization Applications

Clinical Pharmacology &Therapeutics, EarlyView.
Evidence generation for antihyperglycemic therapies in pediatric type 2 diabetes mellitus (T2DM) remains challenging, with most randomized trials failing to demonstrate statistically significant reductions in glycated hemoglobin (HbA1c), partly due to substantial between‐subject variability.
Pieter J. Colin, Efthymios Manolis, Jeroen V. Koomen   +2 more
wiley   +1 more source

Safety and Efficacy of Zetomipzomib in Relapsed or Insufficiently Responding Autoimmune Hepatitis: Results from the Randomised, Double-Blind, Placebo-Controlled, Phase 2a PORTOLA Study and Open-Label Extension

Craig Lammert, Ethan M. Weinberg, Seth N. Sclair, Robert J. Fontana, Neel K. Anand, Janet L. Anderl, David Bade, Shraddha Desai, Chirstopher J. Kirk, Diana Lam, Eric J Lowe, Tony Muchamuel, Kiruthi Palaniswamy, Rachel Peterson, Kathryn Ray, Zung To, Brian B. Tuch, Jennifer A. Whang, A. B. GOEL   +18 more
openalex   +1 more source

Placebo mechanisms in aging: A randomized controlled trial comparing deceptive and open-label placebos on psychological, cognitive, and physical functioning in older adults

Diletta Barbiani, Alessandro Antonietti, Francesco Pagnini   +2 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Open-Label Placebo Treatment for Experimental Pain: A Randomized-Controlled Trial with Placebo Acupuncture and Placebo Pills

Journal of Integrative and Complementary Medicine, 2022
Objective: An open-label placebo (OLP) is a placebo treatment in which the patient is aware that the treatment is a placebo. OLPs are considered effective for reducing pain, and previous studies have shown a stronger placebo effect for placebo ...
Younbyoung Chae, In-Seon Lee, Seo Young Lee   +2 more
exaly   +4 more sources

Even when you know it is a placebo, you experience less sadness: First evidence from an experimental open-label placebo investigation

Journal of Affective Disorders, 2022
BACKGROUND Recent studies demonstrate substantial effects of deceptive placebo on experimentally induced sadness, even on autonomic activity. Whether deception is necessary, remains to be elucidated.
Christiane Hermann, Alexander Winkler, Annelie C Meis   +2 more
exaly   +2 more sources

No open-label placebo effect in insomnia? Lessons learned from an experimental trial

Journal of Psychosomatic Research, 2022
BACKGROUND Open-label placebo (OLP) treatment seems to be effective in several medical conditions but has not yet been investigated in insomnia. Furthermore, it needs to be evaluated whether providing a plausible treatment rationale is essential to ...
Alexander Winkler, Julia Haas, Winfried Rief   +2 more
exaly   +2 more sources